US 7,320,786 B2
Photodynamic therapy treatment for eye disease
James C. Chen, Bellevue, Wash. (US)
Assigned to Light Sciences Oncology, Inc., Snoqualmie, Wash. (US)
Filed on Dec. 07, 2005, as Appl. No. 11/297,880.
Application 11/297880 is a continuation in part of application No. 09/760362, filed on Jan. 12, 2001, abandoned.
Claims priority of provisional application 60/175689, filed on Jan. 12, 2000.
Prior Publication US 2006/0088530 A1, Apr. 27, 2006
Int. Cl. A61K 9/00 (2006.01); A61K 39/395 (2006.01); A01N 43/38 (2006.01)
U.S. Cl. 424—9.6  [424/9.61; 424/143.1; 424/178.1; 514/185; 514/912] 17 Claims
 
1. A method of treating neovascular disease of the eye, comprising:
administering a conjugate to target neovascular tissue of the eye comprising:
a photosensitizing compound selected from the group consisting of chlorines, bacteriochlorophylls, phthalocyanines, porphyrins, purpurins, merocyanines, psoralens, porfimer sodium, delta-aminolevulinic acid protoporphyrin, indocyanine green, benzoporphyrin, methylene blue, toluidine blue, texaphyrins, pyropheophorbide compounds, and verteporfin; and
a targeting moiety that selectively binds to abnormal endothelium, wherein the targeting moiety consists of an antibody or an antibody fragment thereof that binds to a VEGF receptor;
allowing sufficient time for the conjugate to clear from non-targeted tissue of the eye; and
illuminating the eye with a light having a wave length or waveband absorbed by the targeted photosensitizing compound to activate the photosensitizing compound, and
wherein the light has a combination of an intensity of light of less than 500 mW/cm2 and a duration of illumination of about 4 minutes to produce a total fluence of light irradiation from between about 30 J/cm2 to about 25,000 J/cm2 which destroys the targeted neovascular tissue while the non-targeted tissue remains undamaged.